InspireMD, Inc. has transitioned from clinical development to commercial launch with its innovative CGuard Prime carotid stent system, leveraging FDA premarket approval achieved in mid-2025. Despite promising regulatory milestones and expanding U.S. market coverage propelled by favorable clinical data, the company faces significant challenges including steep operating losses, considerable negative cash flows, and capital constraints underscored by going concern disclosures. Internationally, InspireMD maintains a distributor-based model while building its U.S. direct sales infrastructure and planning manufacturing capacity expansion. Intellectual property protections around the MicroNet mesh platform underpin competitive differentiation but legal and regulatory risks remain material. Key near-term developments to monitor include pivotal trial readouts, sales ramp metrics, reimbursement evolution, and production scale-up dynamics.